DE4122166A1 - Verwendung des wirkstoffs flupirtin zur bekaempfung von muskelverspannungen - Google Patents

Verwendung des wirkstoffs flupirtin zur bekaempfung von muskelverspannungen

Info

Publication number
DE4122166A1
DE4122166A1 DE4122166A DE4122166A DE4122166A1 DE 4122166 A1 DE4122166 A1 DE 4122166A1 DE 4122166 A DE4122166 A DE 4122166A DE 4122166 A DE4122166 A DE 4122166A DE 4122166 A1 DE4122166 A1 DE 4122166A1
Authority
DE
Germany
Prior art keywords
flupirtine
muscle tension
antiparkinsonian
optionally
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE4122166A
Other languages
German (de)
English (en)
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Juergen Prof Engel
Peter Dr Emig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva GmbH
Original Assignee
Asta Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma AG filed Critical Asta Pharma AG
Publication of DE4122166A1 publication Critical patent/DE4122166A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
DE4122166A 1990-07-14 1991-07-04 Verwendung des wirkstoffs flupirtin zur bekaempfung von muskelverspannungen Ceased DE4122166A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (OSRAM) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
DE4122166A1 true DE4122166A1 (de) 1992-01-16

Family

ID=25895002

Family Applications (3)

Application Number Title Priority Date Filing Date
DE4122166A Ceased DE4122166A1 (de) 1990-07-14 1991-07-04 Verwendung des wirkstoffs flupirtin zur bekaempfung von muskelverspannungen
DE59109222T Expired - Lifetime DE59109222D1 (de) 1990-07-14 1991-07-04 Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE59107331T Expired - Lifetime DE59107331D1 (de) 1990-07-14 1991-07-04 Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE59109222T Expired - Lifetime DE59109222D1 (de) 1990-07-14 1991-07-04 Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE59107331T Expired - Lifetime DE59107331D1 (de) 1990-07-14 1991-07-04 Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen

Country Status (30)

Country Link
US (2) US5162346A (OSRAM)
EP (2) EP0659410B1 (OSRAM)
KR (1) KR0182811B1 (OSRAM)
CN (1) CN1070700C (OSRAM)
AT (2) ATE133564T1 (OSRAM)
AU (1) AU634073B2 (OSRAM)
CA (1) CA2046943C (OSRAM)
CZ (1) CZ280879B6 (OSRAM)
DE (3) DE4122166A1 (OSRAM)
DK (2) DK0659410T3 (OSRAM)
EG (1) EG19814A (OSRAM)
ES (2) ES2082887T3 (OSRAM)
GR (1) GR3019179T3 (OSRAM)
HR (1) HRP920667B1 (OSRAM)
HU (1) HU206973B (OSRAM)
IE (1) IE74688B1 (OSRAM)
IL (1) IL98810A (OSRAM)
IN (1) IN172468B (OSRAM)
LT (1) LT3593B (OSRAM)
LV (1) LV10048B (OSRAM)
MC (1) MC2272A1 (OSRAM)
MX (1) MX9100160A (OSRAM)
NO (1) NO912758L (OSRAM)
NZ (1) NZ238940A (OSRAM)
PT (1) PT98291B (OSRAM)
RO (1) RO108220B1 (OSRAM)
RU (1) RU2070408C1 (OSRAM)
SI (1) SI9111227B (OSRAM)
SK (1) SK279567B6 (OSRAM)
ZA (1) ZA915466B (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305079A1 (en) * 1992-03-11 1993-09-23 Asta Medica Ag Thioctic acid, mesna and flupirtin maleate solid forms
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
EP1987819A1 (de) 2003-06-20 2008-11-05 AWD.pharma GmbH & Co.KG Injizierbare Darreichungsform von Flupirtin
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
HUP0301296A2 (hu) * 1999-08-03 2003-08-28 Awd.Pharma Gmbh & Co. Kg Flupirtin alkalmazása degeneratív ízületi fájdalom kezelésére
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
WO2007128462A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CA2661462C (en) * 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
JP2010511052A (ja) * 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
NZ582942A (en) * 2007-08-01 2011-09-30 Lundbeck & Co As H Use of kncq potassium channel openers for treating attention deficit hyperactivity disorder (adhd) or aggression
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
NZ787838A (en) 2019-11-08 2025-08-29 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305079A1 (en) * 1992-03-11 1993-09-23 Asta Medica Ag Thioctic acid, mesna and flupirtin maleate solid forms
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
EP1987819A1 (de) 2003-06-20 2008-11-05 AWD.pharma GmbH & Co.KG Injizierbare Darreichungsform von Flupirtin
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
WO2011157719A1 (en) 2010-06-14 2011-12-22 Awd.Pharma Gmbh & Co. Kg An injectable dosage form of flupirtine
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Also Published As

Publication number Publication date
AU8040391A (en) 1992-01-16
HU206973B (en) 1993-03-01
EP0467164B1 (de) 1996-01-31
NO912758D0 (no) 1991-07-12
MC2272A1 (fr) 1993-06-23
EP0467164A3 (en) 1992-04-15
ZA915466B (en) 1992-04-29
LV10048A (lv) 1994-05-10
CA2046943C (en) 1996-03-12
HRP920667B1 (en) 1998-06-30
IL98810A (en) 1996-01-19
KR920002147A (ko) 1992-02-28
CA2046943A1 (en) 1992-01-15
ES2082887T3 (es) 1996-04-01
DE59107331D1 (de) 1996-03-14
EG19814A (en) 1996-02-29
PT98291B (pt) 1999-01-29
MX9100160A (es) 1992-02-28
HU912359D0 (en) 1991-12-30
DK0467164T3 (da) 1996-03-04
IN172468B (OSRAM) 1993-08-14
CS210191A3 (en) 1992-02-19
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
EP0659410B1 (de) 2001-10-17
AU634073B2 (en) 1993-02-11
DK0659410T3 (da) 2001-12-27
EP0659410A2 (de) 1995-06-28
RU2070408C1 (ru) 1996-12-20
DE59109222D1 (de) 2001-11-22
CZ280879B6 (cs) 1996-04-17
EP0659410A3 (de) 1995-10-25
SK279567B6 (sk) 1999-01-11
ATE206919T1 (de) 2001-11-15
RO108220B1 (ro) 1994-03-31
PT98291A (pt) 1992-05-29
LT3593B (en) 1995-12-27
SI9111227B (sl) 2000-12-31
HUT59313A (en) 1992-05-28
IL98810A0 (en) 1992-07-15
ATE133564T1 (de) 1996-02-15
KR0182811B1 (ko) 1999-05-01
NO912758L (no) 1992-01-15
SI9111227A (en) 1995-06-30
LTIP919A (en) 1995-03-27
IE912451A1 (en) 1992-01-15
ES2164111T3 (es) 2002-02-16
CN1058716A (zh) 1992-02-19
US5284861A (en) 1994-02-08
HRP920667A2 (en) 1996-10-31
IE74688B1 (en) 1997-07-30
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
EP0467164A2 (de) 1992-01-22
LV10048B (en) 1995-06-20

Similar Documents

Publication Publication Date Title
EP0659410B1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
EP0241809B1 (de) Synergistische Kombination von Amantadin und Selegilin
JP2024161363A (ja) 安定なカンナビノイド製剤
DE69720985T3 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE4035442A1 (de) Arzneimittel enthaltend als wirkstoff r-(alpha)-liponsaeure oder s-(alpha)-liponsaeure
EP0193056B1 (de) Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
EP0501205B1 (de) Antiphlogistisches Mittel
DD291925A5 (de) Arzneimittel enthaltend als wirkstoff dihydroliponsaeure
DE3719818C2 (de) Pharmazeutische Zusammensetzung
DE4000070A1 (de) Verwendung des wirkstoffs azelastin zur bekaempfung von psoriasis-erkrankungen sowie entzuendungserkrankungen
DE3115383A1 (de) Antiallergisches mittel
DE4013696A1 (de) Salze des azelastins mit verbesserter loeslichkeit
DE3604575A1 (de) Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
EP0277352B1 (de) Synergistische Kombination von Azelastin und Theophyllin oder Azelastin und Beta-Mimetika
DE4029747C2 (de) Verwendung von Hexadecylphosphocholin zur Behandlung von Psoriasis-Erkrankungen
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE68907976T2 (de) Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird.
DE69331008T2 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
DE60309582T2 (de) Verfahren zur herstellung einer einen antiretroviralen proteasehemmer enthaltenden pharmazeutischen zusammensetzung mit verbesserter bioverfügbarkeit
WO2012120082A1 (de) Adenosin und seine derivate zur verwendung in der schmerztherapie
DE69307197T2 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
DE4002706A1 (de) Arzneimittel enthaltend als wirkstoff dihydroliponsaeure
DE4331168A1 (de) Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
DE69302250T2 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia
DE3710966A1 (de) Synergistische kombination von amantadin und selegilin

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: ASTA MEDICA AG, 6000 FRANKFURT, DE

8127 New person/name/address of the applicant

Owner name: ASTA MEDICA AG, O-8020 DRESDEN, DE

8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: AWD.PHARMA GMBH & CO. KG, 01097 DRESDEN, DE

8131 Rejection